Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Oct 11, 2012 12:14pm
196 Views
Post# 20473371

Re:Eye Opener

Re:Eye Opener

Good point with the Tyhee Gold, quickly see a correlation once you look at their corporate make up. As to partnerships, this has been out of flavour with me for sometime. Their are may examples over the last couple of years where I could build the case partnerships are not really a strategic objective of the company, beginning with Posada and Associates back in 2010, which were supposedly brought on board to assist in developing partnerships. One example last Sept, 30,2011 the cmpy provides an update on their Alzhemier's Diagnostic program. " We are actively seeking a development partner to bring this important and valuable new asset to the market as quickly as possible " More than a year from that PR with the cmpy since then reporting the science has never been better and the top biochemical test in the world. I tend to accept the case that these things "take time" for so long then start to look in a different direction. My thoughts are what is going on behind the scenes is final collaborations, " I hope" in validating the Promis technology. The PR in May with a German cmy proves up their VCJD, BSE, animal sciences Assay. This August the cmpy reported " We have increased our Business Development Activities and are actively pursuing "Specific Collaborations" with a number of companies to further " validate" the commercialization of the Assay, probably going on behind the scenes. The JSW life sciences was further validation of their A4 test. So I am holding to the idea that we won't see any partnerships but a take-out until proven wrong, and now that the Cancer testing in amimals is finally underway this might be the last piece. 

Bullboard Posts